Nihan Cuzdan Coskun1, Saime Ay2, Fatma Deniz Evcik3, Derya Oztuna4. 1. Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Cukurova University School of Medicine, Adana, Turkey. 2. Department of Physical Medicine and Rehabilitation, Ufuk University School of Medicine, Ankara, Turkey. 3. Haymana Vocational School, Department of Therapy and Rehabilitation, Ankara University, Ankara, Turkey. 4. Department of Biostatistics, Ankara University School of Medicine, Ankara, Turkey.
Abstract
AIM: The results of previous studies regarding the role of adiponectin in the pathogenesis of osteoarthritis (OA) are controversial. The aim of this study is to investigate the relation of plasma adiponectin levels with clinical and radiological disease severity in knee OA patients. METHOD: Sixty patients with knee OA and 25 healthy controls were included in the study. Patients were divided into two subgroups: lean (Group 1, n = 30) and obese (Group 2, n = 30). Healthy controls were accepted as Group 3 (n = 25). Pain intensity was measured with a visual analogue scale (VAS), functional disability with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Quality of Life (QoL) with Short Form-36 (SF-36). Also all patients were radiologically evaluated and graded according to Kellgren-Lawrence (KL) scale. Plasma concentrations of adiponectin levels were measured by enzyme-linked immune-sorbent assay (ELISA). RESULTS: Serum adiponectin levels were higher in OA patient subgroups than those in the control group but the difference did not reach a significant level after adjustments for age, gender and body mass index (P = 0.078). There was a positive correlation between adiponectin concentration and KL grading scores. Additionally, there was a positive correlation between adiponectin levels and clinical variables (VAS and WOMAC total scores) in patient subgroups (r = 0.326 P = 0.012, r = 0.583 P < 0.001, respectively). SF-36 scores were inversely associated with adiponectin levels. CONCLUSION: Plasma adiponectin concentrations were associated with both clinical and radiological disease severity in knee OA patients. Thus, adiponectin hormone might be a potential clinically useful biomarker while assessing disease severity in the future.
AIM: The results of previous studies regarding the role of adiponectin in the pathogenesis of osteoarthritis (OA) are controversial. The aim of this study is to investigate the relation of plasma adiponectin levels with clinical and radiological disease severity in knee OA patients. METHOD: Sixty patients with knee OA and 25 healthy controls were included in the study. Patients were divided into two subgroups: lean (Group 1, n = 30) and obese (Group 2, n = 30). Healthy controls were accepted as Group 3 (n = 25). Pain intensity was measured with a visual analogue scale (VAS), functional disability with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Quality of Life (QoL) with Short Form-36 (SF-36). Also all patients were radiologically evaluated and graded according to Kellgren-Lawrence (KL) scale. Plasma concentrations of adiponectin levels were measured by enzyme-linked immune-sorbent assay (ELISA). RESULTS: Serum adiponectin levels were higher in OA patient subgroups than those in the control group but the difference did not reach a significant level after adjustments for age, gender and body mass index (P = 0.078). There was a positive correlation between adiponectin concentration and KL grading scores. Additionally, there was a positive correlation between adiponectin levels and clinical variables (VAS and WOMAC total scores) in patient subgroups (r = 0.326 P = 0.012, r = 0.583 P < 0.001, respectively). SF-36 scores were inversely associated with adiponectin levels. CONCLUSION: Plasma adiponectin concentrations were associated with both clinical and radiological disease severity in knee OA patients. Thus, adiponectin hormone might be a potential clinically useful biomarker while assessing disease severity in the future.
Authors: Cristóbal Orellana; Joan Calvet; Antoni Berenguer-Llergo; Néstor Albiñana; María García Manrique; Carlos Galisteo Lencastre; Marta Arévalo; María Llop; Assumpta Caixàs; Jordi Gratacós Journal: Cartilage Date: 2020-02-20 Impact factor: 3.117
Authors: Marianna Vitaloni; Angie Botto-van Bemden; Rosa Maya Sciortino Contreras; Deborah Scotton; Marco Bibas; Maritza Quintero; Jordi Monfort; Xavier Carné; Francisco de Abajo; Elizabeth Oswald; Maria R Cabot; Marco Matucci; Patrick du Souich; Ingrid Möller; Guy Eakin; Josep Verges Journal: BMC Musculoskelet Disord Date: 2019-10-27 Impact factor: 2.362